PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

MLA

Tao Wang, et al. “PPARD Rs2016520 (T/C) and NOS1AP Rs12742393 (A/C) Polymorphisms Affect Therapeutic Efficacy of Nateglinide in Chinese Patients with Type 2 Diabetes Mellitus.” BMC Medical Genomics, vol. 14, no. 1, Nov. 2021, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12920-021-01108-5.

APA

Tao Wang, Jin-Fang Song, Xue-Yan Zhou, Cheng-Lin Li, Xiao-Xing Yin, & Qian Lu. (2021). PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus. BMC Medical Genomics, 14(1), 1–8. https://doi.org/10.1186/s12920-021-01108-5

Chicago

Tao Wang, Jin-Fang Song, Xue-Yan Zhou, Cheng-Lin Li, Xiao-Xing Yin, and Qian Lu. 2021. “PPARD Rs2016520 (T/C) and NOS1AP Rs12742393 (A/C) Polymorphisms Affect Therapeutic Efficacy of Nateglinide in Chinese Patients with Type 2 Diabetes Mellitus.” BMC Medical Genomics 14 (1): 1–8. doi:10.1186/s12920-021-01108-5.